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Recombinant versions of parvovirus B19 capsid
proteins VP1 and VP2 are used for immunodiag-
nostic assays for detection of antiviral antibod-
ies. The immune response to B19 is character-
ized by a gradual loss of antibodies directed
against linear epitopes of VP2. A similar occur-
rence for antibodies raised against VP1 protein
would represent a limitation to serological as-
says incorporating denatured versions of either
viral antigen. Four detection systems for B19 Ig
detection have been developed, including an
IgG enzyme immunoassay (EIA) based on unde-
natured VP2, an immunofluorescence assay
(IFA) based on undenatured VP1, a Western blot
assay incorporating denatured VP1 and VP2, and
an alternative blot system using denatured VP1
but undenatured VP2. Specimens (n = 108) were
tested by all four systems and identical results
were obtained by EIA, IFA, and alternative blot
systems, whereby 75/108 (69%) were B19 IgG-
positive. Twelve B19 IgG-positive specimens,
representing 16% (12/75) of the confirmed posi-
tives, did not react to either viral antigens when
tested by Western blot. It is concluded that these
sera do not react with linear epitopes of VP1 and
VP2 antigens. Eighty-five different specimens,
which had previously been shown to be both
B19 IgM- and IgG-positive by EIA and IFA, were
positive by B19 IgM and IgG Western blot. In the
IgG Western blot assay, 69 reacted with both
VP1 and VP2 and 16 with VP1 only. It is con-
cluded that there is a requirement for at least
one undenatured antigen for the immunological
detection of B19 IgG. J. Med. Virol. 57:179–185,
1999. © 1999 Wiley-Liss, Inc.
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INTRODUCTION
Parvovirus B19 is the causative agent of erythema
infectiosum in humans [Anderson et al., 1983]. The dis-
ease is symptomatically mild in healthy individuals
and is most prevalent during childhood. In adults, in-
fection has sometimes been associated with persistent
arthritis; in addition, the infection can be life-
threatening to the fetus, immunocompromised pa-
tients, and individuals with hematopoetic disorders
due to viral replication in erythroid precursor cells [Le-
frer et al., 1986; Anand et al., 1987; Kurtzman et al.,
1987; Woolf et al., 1989; Serjeant et al., 1993]. Approxi-
mately 60–70% of the adult population is parvovirus
B19 IgG-positive [Brown, 1997].
In the mature virion, structural proteins VP2 and
VP1 compose 95% and 5% of total capsid protein, re-
spectively [Ozawa et al., 1987]. The coding region for
both proteins is located in the right-hand section of the
viral genome where overlapping genes encode both
VP1 and VP2 [Ozawa et al., 1987]. Thus, VP1 protein
contains the entire VP2 amino acid sequence plus an
additional 227 amino acids. The three-dimensional
structure of VP2 capsids alone and VP2 capsid-
globoside receptor complex have been reported and it
has been suggested that epitopes for neutralizing an-
tibodies map onto the capsid surface at regions imme-
diately surrounding the globoside attachment sites
[Chipman et al., 1996].
Immunodiagnostic tests available for parvovirus B19
IgG and IgM detection include enzyme immunoassay
(EIA), immunofluorescent assay (IFA), and Western
blot. These methods rely on the respective antibody
reactivity with either or both of the parvovirus B19
proteins, VP1 (84 kDa) and VP2 (58 kDa). In such tests,
the recombinant proteins used are extracted from ei-
ther E. coli or recombinant baculovirus-infected
Spodoptera frugiperda cells [Morinet et al., 1989;
Brown et al., 1991].
Using denatured VP1- and VP2-based Western blot
tests for detecting parvovirus B19 IgG, it has been ob-
served that in the majority of cases reactivity is con-
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fined to VP1; however, such sera will react with unde-
natured VP2 when used in an EIA [So¨derlund et al.,
1995]. This phenomenon has been confirmed in our
laboratory, which specializes in parvovirus B19 diag-
nostic development and manufacture. Furthermore, it
has been shown that this nonreactivity toward dena-
tured VP2 occurs after about 6–12 months postinfec-
tion, but that prior to this parvovirus B19 IgG will
react with linear epitopes of both denatured VP1 and
VP2 proteins in Western blots [Franssila et al., 1996].
In our laboratory it was also noted that a number of
sera, which gave strongly positive parvovirus B19 IgG
results using EIA and IFA analysis, were negative for
both VP1 and VP2 by Western blot assay. Since the
parvovirus B19 IgG EIA and IFA tests used were based
on undenatured VP2 and VP1 antigens, respectively, it
was suspected that a subpopulation of parvovirus B19
IgG-reactive specimens existed which react with nei-
ther denatured VP1 nor VP2 (i.e., linear epitopes).
This, if true, would suggest that undenatured parvovi-
rus B19 antigens are essential for the accurate detec-
tion of parvovirus B19 IgG.
Consequently, the primary aim of the study was to
confirm the existence of a parvovirus B19 IgG EIA/IFA-
positive and Western blot-negative population. To this
end, a panel of normal human sera was tested for par-
vovirus B19 IgG using the three diagnostic methods
described and an alternative blot system that utilized
undenatured VP2. Undenatured VP1 could not be in-
cluded in this latter assay due to the solubilization
steps necessary in purification from S. frugiperda cells.
Secondly, it was decided to ascertain if a similar phe-
nomenon was evident for parvovirus B19 IgM detection
using Western blot analysis.
MATERIALS AND METHODS
Antigen Production
Parvovirus B19 recombinant VP1 and VP2 capsid
proteins were expressed in the baculovirus expression
system for use in this study [Brown et al., 1990, 1991].
Recombinant VP1 infected cells were either utilized di-
rectly for slide preparation (immunofluorescence as-
say) or else extracted under denaturing conditions to
produce purified VP1 protein for nitrocellulose strip
preparation (Western/alternative blot). Insect cells ex-
pressing recombinant VP2 were lysed and the VP2 cap-
sids purified under nondenaturing conditions for use in
enzyme immunoassay or Western/alternative blot
preparation.
Baculovirus expression of parvovirus B19 pro-
teins. Recombinant baculoviruses (VP1 recombinant
and VP2 recombinant) are each used to infect sepa-
rately monolayers of Sf9 cells (ATCC CRL 1711) in TC-
100 medium containing 10% fetal calf serum [Brown et
al., 1990].
VP1 purification. Infected Sf9 cells were har-
vested 3 days postinfection and lysed by sonication in
phosphate-buffered saline. Cell debris and insoluble
VP1 protein were pelleted by centrifugation at 3,000 g
for 10 min. After extensive washing with phosphate-
buffered saline to remove soluble proteins, the in-
soluble VP1 protein was resuspended and dissolved in
PBS/6-M guanidine-HCL and dialyzed with 6-M urea
prior to SDS-PAGE [Laemmili et al., 1970] and electro-
transfer [Towbin et al., 1979] to generate Western blot
strips. This material was also used to prepare alterna-
tive blot strips using an airjet spray system (Airjet
Model XY3000; Biodot, U.K.).
VP2 purification. Infected Sf9 cells were har-
vested 3 days postinfection and lysed by sonication in
phosphate-buffered saline. Removal of cell debris was
achieved by centrifugation at 3,000 g for 10 min and
the resultant supernatant was layered onto a 15–30%
(w/v) sucrose gradient and centrifuged for 3 hr at
100,000 g. Pellets containing capsid VP2 were collected
and used for enzyme immunoassay, alternative blot,
and Western blot preparation.
Immunoassay Formats
A number of immunoassay formats were developed
for the detection of parvovirus B19 antibodies. All the
diagnostic kits used in this study and described below
were obtained from Biotrin International (Mount Mer-
rion, Dublin, Ireland).
Parvovirus B19 IgG enzyme immunoassay. The
parvovirus B19 IgM enzyme immunoassay is a direct
enzyme immunoassay for the detection of IgG-class an-
tibodies to parvovirus B19 in human serum and
plasma. Parvovirus B19 IgG, present in serum or
plasma, diluted 1/100, was bound to microwells that
had been precoated with recombinant VP2 capsids. Fol-
lowing a wash step, horseradish peroxidase (HRP)-
labeled rabbit antihuman IgG was added, which bound
to the IgG present. This complex was then detected by
addition of tetramethyl benzidine (TMB) substrate.
Sulfuric acid addition terminated the reaction after 10
min followed by absorbance measurement at 450 nm.
Specimens with an index value (specimen/cutoff absor-
bance ratio) greater than 1.1 were deemed positive.
Parvovirus B19 IgM enzyme immunoassay.
The parvovirus B19 IgM enzyme immunoassay is a
m-capture enzyme immunoassay for the detection of
parvovirus B19 IgM in human serum and plasma (1/
100 dilution). Microwells were precoated with rabbit
antihuman IgM and total serum IgM was bound to the
solid phase. Following a wash step, biotinylated parvo-
virus B19 VP2 capsids were added, which bound to any
parvovirus B19 IgM present. After another wash step,
streptavidin-peroxidase was added, which bound to the
biotinylated VP2 present. This complex was then de-
tected by addition of TMB substrate. Sulfuric acid ad-
dition terminated the reaction after 10 min followed by
absorbance measurement at 450 nm. Specimens with
an index value (specimen/cutoff absorbance ratio)
greater than 1.1 were deemed positive.
Parvovirus B19 IgG/IgM immunofluorescence
assay. The parvovirus B19 immunofluorescence as-
say utilizes an indirect immunofluorescence antibody
technique whereby the specimen is incubated with par-
vovirus B19 recombinant VP1 capsid antigen in insect
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cells, previously stabilized on a glass slide [Brown et
al., 1990]. The presence of parvovirus B19 antibodies in
the sample led to the formation of a stable complex
with VP1 antigen. Bound antibody was then reacted
with a fluorescein-labeled antihuman IgG or IgM and
the complex was visualized with the aid of a fluores-
cence microscope. Note that parvovirus B19 IgG was
removed prior to parvovirus B19 IgM analysis.
Parvovirus B19 IgG/IgM Western blot. The
Western blot immunoassay utilizes recombinant VP1
and VP2 viral antigens purified from baculovirus in-
fected S. frugiperda cells that are electrotransfered
onto nitrocellulose after SDS-PAGE. Any parvovirus
B19 antibodies present in the human serum specimen
bound to the immobilized antigens. After a wash step
to remove any unbound antibody, HRP-conjugate (an-
tihuman IgG or IgM) was added to the membrane. The
bound antibody-conjugate complex was detected by the
addition of the precipitating substrate diaminobenzi-
dine tetrahydrochloride and H2O2. A positive result
was indicated by the appearance of bands correspond-
ing to the position of either or both VP1 and VP2 anti-
gens. Note that parvovirus B19 IgG was removed prior
to parvovirus B19 IgM analysis.
Parvovirus B19 IgG alternative blot system.
This blot system utilizes purified recombinant VP1 and
VP2 viral antigens obtained from infected S. frugi-
perda cells. Denatured VP1 antigen and undenatured
VP2 capsids were sprayed separately as two bands onto
nitrocellulose membrane using an airjet system. The
assay procedure was identical to the Western blot Ig
assay described above.
Comparison of EIA, IFA, and two blot methods
for the detection of parvovirus B19 IgG in sera
obtained from a blood donor population. Donor
sera (n 4 108) were obtained from the Irish Blood
Transfusion Service within 2 days of donation and were
screened for parvovirus B19 IgG using the EIA based
on undenatured VP2, IFA based on undenatured VP1,
Western blot based on denatured VP1 and VP2, and
the alternative blot format based on denatured VP1
and undenatured VP2 sprayed onto nitrocellulose
without undergoing the denaturation inherent in elec-
trophoresis.
Detection of parvovirus B19 IgM and IgG using
Western blot assays in sera shown to be EIA- and
IFA-positive for both antibody classes. Specimens
(n 4 85) obtained from German clinical laboratories
and which were shown to be positive by the aforemen-
tioned EIA and IFA test systems for both parvovirus
B19 IgM and IgG, indicative of recent infection, were
tested by Western blot. The parvovirus B19 IgG West-
ern blot assays were performed to verify if parvovirus
B19 IgG is reactive with both denatured proteins dur-
ing such early convalescence and to investigate if any
of these sera did not react with either or both dena-
tured antigens.
Substantiation that denaturation of VP2 using
the denaturing reagents used in VP1 purification
would not have unexpected affects on parvovirus
B19 IgM or IgG reactivity with VP2. VP2 purified
following the usual VP2 nondenaturing purification
procedure described earlier was denatured with guani-
dine hydrochloride and dialyzed with urea as per the
VP1 solubilization method. Guanidine/urea-solubilized
VP1 and VP2 was then used in IgG and IgM Western
blots and the alternative IgG blot assay. The following
four sample groups were tested, the first two for B19
IgM and IgG and the remaining two for B19 IgG only.
The B19 IgM and IgG status of these samples had been
previously determined by the Biotrin parvovirus B19
EIA, Western blot, and the alternative B19 IgG assays
described previously. Group 1 includes B19 IgM/IgG-
negative sera (n 4 5); Group 2, B19 IgM/IgG-positive
sera (n 4 10); Group 3, B19 IgG-positive/IgM-negative
sera (n 4 5), which were VP1-reactive, VP2-unreactive
on B19 IgG Western blots; Group 4, B19 IgG-positive/
IgM-negative sera (n 4 5), which did not react with
either VP1 or VP2 on B19 IgG Western blots.
RESULTS
The results for the comparison of the four detection
methods for parvovirus B19 IgG in 108 blood donor
sera are presented in Table I. This analysis indicates
an overall parvovirus B19 IgG seropositivity rate of
69%; in addition, identical serological results are ob-
tained from the EIA, IFA, and alternative blot systems.
However, 12 parvovirus B19 IgG-positive specimens,
TABLE I. Detection of Parvovirus B19 IgG by EIA, IFA, Western Blot
(WB), and an Alternative Blot System (AB) in 108 Normal Human Sera
Test result Number (%)
Parvovirus B19 IgG detection system
EIAa IFAa WBa ABa
Total positive 75 (69%)
Positive (Group 1) 63 + + +b +
Positive (Group 2) 12 + + − +c
Total negative 33 (31%) − − − −
aEIA: parvovirus B19 IgG enzyme immunoassay (utilizes undenatured VP2 antigen).
IFA: parvovirus B19 IgG immunofluorescence assay (utilizes undenatured VP1 an-
tigen). WB: parvovirus B19 IgG Western blot assay (utilizes denatured VP1 and VP2
antigens). AB: parvovirus B19 IgG alternative blot assay (utilizes denatured VP1 and
undenatured VP2 antigen, respectively).
bAll 63 sera were reactive with VP1 only.
cAll 12 sera were reactive with VP2 only.
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which represent 16% (12/75) of the confirmed positives,
did not react to linear epitopes on either denatured
VP1 or VP2 antigens when tested by Western blot.
The results for the comparison of the EIA, IFA, and
Western blot methods for the detection of IgM and IgG
in 85 sera are presented in Table II. All 85 sera con-
tained both parvovirus B19 IgG and IgM as judged by
all three test methods.
The reactivity incidence of parvovirus IgM and IgG
with VP1 and VP2 in the Western blot assay for 85 sera
is presented in Table III. Parvovirus B19 IgM reactiv-
ity against both VP1 and VP2 proteins was observed
for all the specimens. However, upon testing for parvo-
virus B19 IgG only 69/85 (81%) of specimens were re-
active against both viral antigens. Of the remaining
specimens, 16/85 (19%) were reactive with VP1 only.
Examples of parvovirus B19 IgG results for sera
tested by both Western blot and the alternative blot
format are illustrated in Figures 1 and 2, respectively.
There were four groups of result (A, B, C, and D) and
three examples are shown for each. The parvovirus B19
IgG EIA and IFA result is also given for each Group
(A–D). Group A individuals were reactive with VP1 and
VP2 in both blot formats; these specimens were also
parvovirus B19 IgM-positive. Group B individuals were
VP1-positive in both blot formats but are only reactive
with undenatured VP2 in the alternative blot format
(Fig. 2). Group C individuals do not react with dena-
tured VP1 and VP2 following Western blot analysis but
reactive with undenatured VP2 in the alternative blot
format. Group D are individuals who do not react with
VP1 and VP2 in both blot systems and also when tested
by parvovirus B19 IgG EIA and IFA. The banding pat-
tern seen in Figure 1 for Group A and B specimens is
due to parvovirus B19 IgG reactivity with degradation
fragments of the VP1 protein. This pattern is not evi-
dent in the alternative blot format as the viral antigens
are sprayed directly onto the nitrocellulose membrane.
The comparison of results between assays tested
against undenatured VP2 and guanidine HCL/urea-
denaturated VP2 is presented in Table IV. This dena-
turation made no difference to the results, except in the
Group 3 sera. These Group 3 sera did not react with
denatured VP2, when it was used in the alternative
IgG blot system. This result was expected since these
sera did not react with VP2 denatured with SDS-PAGE
reagents by the original B19 IgG Western blot format.
DISCUSSION
This study has demonstrated for the first time that
parvovirus B19 IgG from some individuals does not
react against linear epitopes on both denatured parvo-
virus B19 VP1 and VP2 antigens. This finding is of
significance as it clearly demonstrates the absolute re-
quirement for the use of at least one undenatured an-
tigen in immunodiagnostic tests designed for the de-
tection of parvovirus B19 IgG. Moreover, it was dem-
onstrated that either parvovirus B19 VP1 or VP2
capsid structure is sufficient for the attainment of
maximum assay sensitivity given the high degree of
correlation (100%) between the different immunoassay
formats.
From 108 sera that had been confirmed as parvovi-
rus B19 IgG-positive by the alternative test methods,
12 did not react by Western blot (Table I). These sera
were mostly strong positives by the other tests, thus
eliminating the possibility of blot insensitivity as an
explanation for the result. Furthermore, the antihu-
man IgG peroxidase conjugate used for both parvovirus
B19 IgG Western blot and EIA was obtained from the
same source, which confirms that differential conju-
gate reactivity is not responsible for the observed re-
sults. All 12 of these sera were detectable when non-
denatured VP2 was used in the alternative blot format.
Unfortunately, it was not possible to incorporate non-
denatured VP1 into this format because denaturation
is inherent to the VP1 purification process from bacu-
lovirus-infected insect cells. Western blots prepared
from unpurified VP1, obtained by electrophoresis of in-
fected S. frugiperda cell lysates, were tested with the
unreactive parvovirus B19 IgG specimens (n 4 12).
The results (not presented) were consistent with initial
Western blot analysis whereby none of the 12 reacted
against denatured VP1, which demonstrates that the
observed lack of reactivity is not an artifact of the VP1
purification process. Finally, all 63 sera that were par-
vovirus B19 IgG-positive by Western Blot were reactive
with VP1 only.
After identifying the occurrence of Western blot par-
vovirus B19 IgG nonreactivity, it was logical to inves-
tigate if there was a similar incidence with parvovirus
B19 IgM detection using Western blot. The study of the
85 parvovirus B19 IgM EIA- and IFA-positive sera
showed that all were detectable by a Western blot as-
say (Table II). In each case, both denatured antigens
were reactive (Table III). These 85 parvovirus B19 IgM
specimens had also been confirmed as parvovirus B19
IgG-positive and when assayed for parvovirus B19 IgG
by Western blot all were reactive (Table II). Sixteen of
these sera reacted with VP1 only and the remaining 69
reacted with both antigens (Table III).
The parvovirus B19 IgG Western blot results for the
sera shown to be IgM-positive confirmed other investi-
gators’ observations that during an early postinfection
period, the IgG is reactive with both denatured VP1
and VP2 in most cases [So¨derlund et al., 1995]. It may
be of significance that there were no Western blot IgG
TABLE II. Parvovirus B19 IgM and IgG Positivity for 85
Specimens Tested by EIA, IFA, and Western Blot for the
Respective Antibody Classes
Test result
Parvovirus B19
detection systema
EIA IFA Western blot
Parvovirus B19 IgM-positive 85 85 85
Parvovirus B19 IgG-positive 85 85 85
aEIA: parvovirus B19 IgG enzyme immunoassay. IFA: parvovirus B19
IgG immunofluorescence assay.
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false negatives in this group, in contrast to those ob-
served in the blood donor population tested. From
these results it is possible to understand that the par-
vovirus B19 IgG nonreactivity with denatured VP2,
and in some cases denatured VP1 and VP2, occurs after
the early postinfection period. To substantiate this hy-
pothesis, parvovirus B19 IgM and IgG seroconversion
panels will have to be tested.
The study on the effect on B19 IgM or IgG reactivity
with VP2 when it was denatured using the denaturing
reagents used in VP1 purification (Table IV) showed
that this denaturation had no significant affect on VP2
antigenicity, except as expected, when it was shown to
eliminate VP2 reactivity with those B19 IgG-positive
cases that also did not react with VP2 denatured by
SDS-PAGE reagents by Western blot assays (Group 3
sera).
So¨derlund et al. [1995] also compared parvovirus
B19 IgG immunoreactivity between denatured and un-
denatured VP1. These investigators concluded that de-
naturation had little effect on VP1 antigenicity. How-
ever, these conclusions were primarily obtained using
serum pools and since the majority of parvovirus B19
IgG-positive specimens are reactive to denatured VP1,
it is possible that they masked specimens lacking re-
activity with linear epitopes of VP1. Furthermore, it
may also be of significance that these previous studies
used either the unique region of VP1 (as a b-galactosi-
dase fusion protein) or a VP1/2 capsid combination,
which may explain why So¨derlund et al. [1995] did not
make the observations regarding absence of reactivity
against linear epitopes of VP1.
An interesting explanation was given by So¨derlund
et al. [1995] for the absence of parvovirus B19 IgG im-
munoreactivity with denatured VP2 in late convales-
cence. The hypothesis was that denatured VP2 has a
‘‘self ’’ component and that after a transient breach of
immunologic tolerance during early infection, immuno-
reactivity becomes confined to the VP1 unique region.
The present study has shown that IgG reactivity to-
ward linear epitopes on VP1 also undergoes temporal
diminution. It would be tempting to speculate if the
TABLE III. Parvovirus B19 IgM and IgG Western Blot Results Expressed in Terms
of VP1 and VP2 Reactivity, Respectively for the 85 Specimens Presented in Table II
Western blot result
Antigen reactivity pattern
Number
VP1+/VP2+
(%)
Number
VP1+/VP2−
(%)
Number
VP1−/VP2+
(%)
Number
VP1−/VP2−
(%)
Parvovirus B19 IgM-positive 85 (100%) 0 0 0
Parvovirus B19 IgG-positive 69 (81%) 16 (19%) 0 0
Fig. 1. Examples of results for sera tested for parvovirus B19 IgG using a Western blot that employs denatured VP1 and VP2 proteins for
antibody capture. The parvovirus B19 IgG EIA and IFA result is also presented for each specimen. Group A: parvovirus B19 IgM- and
IgG-positive specimens (Western blot-positive). Group B: parvovirus B19 IgG-positive specimens (Western blot-positive). Group C: parvovirus
B19 IgG-positive specimens (Western blot-negative). Group D: parvovirus B19-negative specimens. Sample ID: unique specimen identification
number. IgG index result: specimens with an index value (specimen/cutoff absorbance ratio) greater than 1.1 are deemed positive. Index value
less than 0.9 implies negative result. IgG IFA result denotes fluorescence intensity: +, positive; 3+ or 4+, medium positive; 5+, strong positive.
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unusual reactivity of parvovirus B19 IgG between lin-
ear and conformational epitopes is of medical signifi-
cance, particularly in relation to autoimmune diseases
to which the virus has been linked [To¨ro¨k, 1997].
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